Copyright STAT
Pfizer on Monday said it filed a second lawsuit against Novo Nordisk and obesity startup Metsera, alleging that Novo’s attempt to outbid Pfizer to acquire the biotech is anticompetitive. The pharma giant alleges that Novo is trying to maintain its dominant position in the obesity market by eliminating Metsera, a potential competitor. It also alleges that Metsera’s controlling shareholders — organizations and funds under Population Health Partners and ARCH Venture Partners — conspired with Metsera and Novo, according to the lawsuit, filed in the United States District Court for the District of Delaware. Advertisement In a statement, Pfizer said that the move by Novo, a Danish company, is “capturing and killing a nascent American competitor before it gains the support of Pfizer, one of America’s leading pharmaceutical companies.”
